ClinicalTrials.gg
AvailableNCT07137559ADAPTUpdated Aug 22, 2025

CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

An expanded access record providing CELZ-201-DDT in Chronic Back Pain and Degenerative Disc Disease Lumbar, sponsored by Creative Medical Technology Holdings Inc. Available. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Creative Medical Technology Holdings Inc · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
Ages
18 Years to 80 Years
Sex
All
01

Study summary

CELZ-201-DDT is an investigational (experimental) cell therapy currently being studied for people with degenerative disc disease who have chronic lower back pain.

Read the detailed description

Expanded Access to CELZ-201-DDT (Allogeneic Umbilical Cord Sub-Epithelial Cell-Derived Mesenchymal Stromal Cells) is available for individual patients with serious or life-threatening chronic lower back pain due to degenerative disc disease (DDD) who have no comparable or satisfactory alternative therapy options.

Requests will be considered on a case-by-case basis under a single-patient IND in coordination with the U.S. Food and Drug Administration (FDA) and an Institutional Review Board (IRB).

For non-emergency requests, the treating physician must submit FDA Form 3926 and obtain FDA authorization before initiating treatment.

For emergency use, treatment may begin without prior FDA authorization if criteria for emergency use are met; the physician must notify the FDA within 5 working days after treatment.

02

Conditions studied

  • Chronic Back Pain
  • Degenerative Disc Disease Lumbar

Keywords

  • CELZ-201-DDT
  • Allogeneic Umbilical Cord Sub-Epithelial Cell-Derived Mesenchymal Stromal Cells
  • Mesenchymal Stromal Cells (MSC)
  • Chronic Lower Back Pain
  • Degenerative Disc Disease (DDD)
  • Lumbar Degeneration
  • Chronic Pain
  • Expanded Access
  • Single Patient IND
  • Emergency Use IND
  • Non-Emergency Use IND
  • Compassionate Use
  • Regenerative Medicine
  • Stem Cell Therapy
03

In context

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

Creative Medical Technology Holdings Inc is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of chronic lower back pain due to degenerative disc disease.
  • No comparable or satisfactory alternative therapy available. Unable to participate in the ongoing CELZ-201-DDT clinical trial. provided.

Exclusion criteria

Exclusion Criteria:

  • Any medical condition that poses an unacceptable risk or would interfere with treatment safety or evaluation.
  • Known to any component of the product.

How to Request Access:

  • Contact the Expanded Access Coordinator to confirm eligibility and discuss feasibility.
  • Complete and submit FDA Form 3926 to the appropriate FDA review division.
  • Obtain IRB review (may be expedited or post-treatment for emergency use). Coordinate drug shipment and treatment schedule.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • DrugCELZ-201-DDT

    CELZ-201-DDT is administered via intramuscular injection. Dosing, administration, and follow-up will be determined by the treating physician in accordance with the EA authorization and medical judgment. Safety monitoring will be performed during and after treatment, and all serious adverse events will be reported to the FDA and IRB per applicable regulations.

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT07137559
Lead sponsor
Creative Medical Technology Holdings Inc
Responsible party
Sponsor
First posted
Aug 22, 2025
Last update
Aug 22, 2025

Study contacts

Creative Medical Technology
Contact
expandedaccess@creativemedicaltechnology.com
(702) 588-1890
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion